T. Rowe Price Funds SICAV - Global Focused Growth Equity Fund Q2 EURRegister to Unlock Ratings |
Performance History | 30/09/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 46.1 | 11.2 | -20.3 | 19.4 | 12.8 | |
+/-Cat | 22.4 | -3.4 | -2.3 | 3.4 | 3.4 | |
+/-B’mrk | - | -6.9 | -1.4 | -2.9 | -1.6 | |
Category: Global Large-Cap Growth Equity | ||||||
Category Benchmark: Morningstar Gbl Growth TME ... |
Key Stats | ||
NAV 29/10/2024 | EUR 21.57 | |
Day Change | 0.05% | |
Morningstar Category™ | Global Large-Cap Growth Equity | |
ISIN | LU1956839051 | |
Fund Size (Mil) 29/10/2024 | USD 4157.20 | |
Share Class Size (Mil) 29/10/2024 | EUR 6.04 | |
Max Initial Charge | - | |
Ongoing Charge 24/10/2024 | 0.77% |
Investment Objective: T. Rowe Price Funds SICAV - Global Focused Growth Equity Fund Q2 EUR |
To increase the value of its shares, over the long term, through growth in the value of its investments. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
David Eiswert 01/10/2012 | ||
Nabil Hanano 01/01/2020 | ||
Inception Date 27/02/2019 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI ACWI NR USD | Morningstar Gbl Growth TME NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for T. Rowe Price Funds SICAV - Global Focused Growth Equity Fund Q2 EUR | 30/09/2024 |
|
|
Top 5 Holdings | Sector | % |
Eli Lilly and Co | Healthcare | 5.89 |
Microsoft Corp | Technology | 4.08 |
Apple Inc | Technology | 4.02 |
Advanced Micro Devices Inc | Technology | 3.23 |
ConocoPhillips | Energy | 2.91 |
Increase Decrease New since last portfolio | ||
T. Rowe Price Funds SICAV - Global Focused Growth Equity Fund Q2 EUR |